Neuro-Oncology News

Patients with advanced cancer should receive dedicated, early palliative care concurrently with standard oncology treatment, according to ASCO’s updated guidelines published in Journal of Clinical Oncology.

Approximately 22.1% of childhood brain tumor survivors developed at least one endocrine disorder within 5 years after diagnosis, according to a nationwide, multicenter study.

Reduced-dose craniospinal irradiation plus a tumor bed boost preserved intellectual functioning in children with wingless or Group 4 subtypes of medulloblastoma, according to research published in the Journal of Clinical Oncology.

Patients with cancer may have an increased risk for treatment-related and -unrelated injuries in the periods preceding and following their cancer diagnosis, according to the results of a registry study conducted in Sweden.

The FDA has announced several decisions related to hematology and oncology treatments in the past 2 weeks.

The FDA has awarded 21 clinical research grants for orphan drugs, encompassing more than $23 million during the course of the next 4 years, to develop products for patients with rare diseases, according to a press release.

Hyperfractionated craniospinal radiotherapy, combined with induction and maintenance chemotherapy, conferred positive OS outcomes in children and adolescents with metastatic medulloblastoma, according to prospective study results published in Journal of Clinical Oncology.

COPENHAGEN, Denmark — Targeted treatment with dabrafenib induced a high rate of response and appeared safe in pediatric patients with BRAF V600–mutated relapsed or refractory low-grade glioma, according to the final results phase a phase 1/phase 2 study presented at the European Society for Medical Oncology Congress.

Andrew Sloan, MD, received the Neuro-Oncology Award at the Annual Meeting of the Congress of Neurological Surgery.

COPENHAGEN, Denmark — The HemOnc Today and Healio.com/HemOnc team will present comprehensive live coverage from the annual ESMO congress.